BioSpace News Archive

CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, announced today that it has enrolled and treated its first US patient in the RESTORE Clinical Study, a safety and technical feasibility evaluation of the CurvaFix® Intramedullary Rodscrew for fixation of pelvic and acetabular fractures.

Dual Focus Imaging Now Available with a Slimmer Profile, Short Bending Section, and Tighter Angulation to Expand Capability in Minimally Invasive Procedures, including Endoscopic Submucosal Dissection (ESD)

VAXXITEK® HVT+IBD+ILT is the first vaccine to offer protection in one shot from Infectious Laryngotracheitis, Marek’s Disease and Infectious Bursal Disease

Elucid Bioimaging Inc. (“Elucid Bio”) today announced that vascuCAP, Elucid Bio’s AI-enabled software for evaluating atherosclerotic plaque stability from CTA, has been added to the IBM Imaging AI Marketplace, an IBM Watson Health® solution.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), announced today that its President and Chief Executive Officer, Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the BIO Investor Forum, held virtually October 13-15, 2020.

CorroHealth expands its Clinical Revenue Integrity solutions with the purchase of the analytics platform and review solutions from TCP Services and Analytics (“TCP”).

In lieu of an in-person update to the media, Dr. Theresa Tam , Canada’s Chief Public Health Officer, issued the following statement today: “There have been 173,123 cases of COVID-19 in Canada , including 9,541 deaths. Over the past week, labs across Canada have tested an average of over 71,000 people daily, with 2.5% testing posit

Exogenesis Corporation today announced that a series of challenge tests for the Exogenesis Surgical Mask (ESM) achieved its primary endpoints of trapping and deactivating COVID-19 viral particles in simulated real-world exposures. The Exogenesis Surgical Mask (ESM) is designed to provide protective nose and mouth covering for h

American Gene Technologies (AGT) a cutting-edge cell and gene therapy company in Rockville, Maryland announced today that CEO Jeff Galvin will present at the annual Cell & Gene Meeting on the Mesa. The meeting will be held virtually October 12-16. Galvin’s presentation will highlight the company’s technology, including AGT103-T, a therapeutic intended to cure HIV, which is scheduled to begin Phase 1 clinical trials this month. Specifics

Real-Time Analyzers, Inc., (RTA) developer of chemical and biological agent analyzers for the U.S. military, today announced that the company has developed a simple-to-use saliva-based COVID-19 test kit.